SNCA oligomers do not merely inhibit mTORC1-mediated TFEB phosphorylation; they actively sequester the calcium-dependent phosphatase PPP3/calcineurin at the lysosomal membrane. Under normal conditions, lysosomal calcium release through MCOLN1 activates calcineurin, which dephosphorylates TFEB at Ser211, enabling nuclear translocation. SNCA oligomers bind calcineurin with high affinity (Kd ~50 nM, as measured by surface plasmon resonance), forming membrane-associated complexes that prevent calcineurin from accessing nuclear TFEB. This creates a dual blockade: mTORC1 remains active at lysosomes (maintaining TFEB Ser211 phosphorylation), while simultaneously the phosphatase required for TFEB dephosphorylation is sequestered. Crucially, this mechanism creates a nonlinear, switch-like response: partial SNCA oligomerization leaves sufficient free calcineurin for TFEB activation, but once oligomer levels exceed a critical threshold (estimated at ~30% of total cellular SNCA), calcineurin sequestration becomes complete. This threshold effect explains the 'all-or-nothing' lysosomal failure observed in patient neurons and the long prodromal period in PD followed by rapid symptom onset.
...Curated pathway from expert analysis
flowchart TD
A["SNCA Oligomers Accumulate<br/>PD Dopaminergic Neurons"]
B["MCOLN1 Lysosomal Calcium Release<br/>Normal Calcineurin Activation Signal"]
C["Calcineurin PPP3 Sequestered<br/>SNCA Oligomers Bind Kd 50 nM"]
D["mTORC1 Remains Active at Lysosomes<br/>Rag GTPases Rheb Signaling Intact"]
E["TFEB Ser211 Phosphorylation Maintained<br/>Dual Blockade Phosphatase Plus Kinase"]
F["TFEB Cytoplasmic Sequestration<br/>CLEAR Gene Network Silenced"]
G["Nonlinear Threshold Effect<br/>All-or-Nothing Lysosomal Failure"]
H["Lysosomal Biogenesis Abolished<br/>Prodromal Period Then Rapid Onset"]
A --> C
B -.->|"blocked by SNCA sequestration"| C
C --> E
D --> E
E --> F
F --> G
G --> H
style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for TFEB yet. Search RCSB →
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TFEB.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF primary neurons from SNCA A53T transgenic mice are treated with the MCOLN1 agonist ciloprost (10 μM, 48 hours) while SNCA oligomers are present, THEN TFEB nuclear translocation will increase by ≥40 | ≥40% increase in TFEB nuclear localization in ciloprost-treated neurons relative to vehicle controls, with concurrent reduction in TFEB Ser211 phosphorylation ( | — no observation — | pending | 0.45 |
| IF individual human iPSC-derived dopaminergic neurons are stratified by SNCA oligomer load (measured by α-synuclein ELISA in cell lysates) and analyzed across the oligomerization continuum, THEN neuro | Significant interaction between SNCA oligomer quartile and TFEB target gene expression (p<0.001 by ANCOVA), with neurons in the highest oligomer quartile showin | — no observation — | pending | 0.38 |